Asymmetric dimethylarginine in psychiatric disorders

Daniel Braun; Jens Schlossmann; Ekkehard Haen

doi:10.1016/j.psychres.2021.113901

Asymmetric dimethylarginine in psychiatric disorders

Psychiatry Res. 2021 Jun:300:113901. doi: 10.1016/j.psychres.2021.113901. Epub 2021 Mar 23.

Authors

Daniel Braun¹, Jens Schlossmann², Ekkehard Haen³

Affiliations

¹ Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Regensburg, Universitätsstrasse 31, 93053 Regensburg, Germany. Electronic address: daniel.braun@ukr.de.
² Department of Pharmacology and Toxicology, Institute of Pharmacy, University of Regensburg, Universitätsstrasse 31, 93053 Regensburg, Germany.
³ Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Regensburg, Universitätsstrasse 31, 93053 Regensburg, Germany.

PMID: 33819866
DOI: 10.1016/j.psychres.2021.113901

Abstract

Serum concentrations of asymmetric dimethylarginine (ADMA) in patients with schizophrenia, schizoaffective disorder, bipolar disorder, and depression were determined and compared to serum concentrations in healthy individuals. In all psychiatric diseases investigated, the ADMA concentration was elevated compared to the control group. Patients with recurrent depressive disorder had higher ADMA levels than patients with only one depressive episode. No differences between women and men were found. The elevated ADMA levels suggest that ADMA is involved in the pathophysiology of psychiatric diseases.

Keywords: Depression; Schizoaffective disorder; Schizophrenia.

MeSH terms

Arginine / analogs & derivatives
Bipolar Disorder*
Female
Humans
Male
Psychotic Disorders*
Schizophrenia*

Substances

N,N-dimethylarginine
Arginine